

BCL9 Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a partial recombinant BCL9.

Catalog # AT1286a

Specification

BCL9 Antibody (monoclonal) (M01) - Product Information

Application	IF, WB, E
Primary Accession	O00512
Other Accession	NM_004326
Reactivity	Human
Host	mouse
Clonality	Monoclonal
Isotype	IgG1 kappa
Calculated MW	149290

BCL9 Antibody (monoclonal) (M01) - Additional Information**Gene ID** 607**Other Names**

B-cell CLL/lymphoma 9 protein, B-cell lymphoma 9 protein, Bcl-9, Protein legless homolog, BCL9

Target/Specificity

BCL9 (NP_004317, 1036 a.a. ~ 1135 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Dilution

WB~~1:500~1000

Format

Clear, colorless solution in phosphate buffered saline, pH 7.2 .

Storage

Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.

Precautions

BCL9 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.


BCL9 Antibody (monoclonal) (M01) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)

- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


BCL9 Antibody (monoclonal) (M01) - Images



Immunofluorescence of monoclonal antibody to BCL9 on HeLa cell. [antibody concentration 10 ug/ml]



Antibody Reactive Against Recombinant Protein. Western Blot detection against Immunogen (36.74 KDa) .



Detection limit for recombinant GST tagged BCL9 is approximately 0.03ng/ml as a capture antibody.

BCL9 Antibody (monoclonal) (M01) - Background

BCL9 is associated with B-cell acute lymphoblastic leukemia. It may be a target of translocation in

B-cell malignancies with abnormalities of 1q21. Its function is unknown. The overexpression of BCL9 may be of pathogenic significance in B-cell malignancies.

BCL9 Antibody (monoclonal) (M01) - References

Allosteric remodelling of the histone H3 binding pocket in the Pygo2 PHD finger triggered by its binding to the B9L/BCL9 co-factor. Miller TC, et al. *J Mol Biol*, 2010 Sep 3. PMID 20637214. Variation at the NFATC2 Locus Increases the Risk of Thiazolinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. *Diabetes Care*, 2010 Jul 13. PMID 20628086. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Rose JE, et al. *Mol Med*, 2010 Jul-Aug. PMID 20379614. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Talmud PJ, et al. *Am J Hum Genet*, 2009 Nov. PMID 19913121. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Mani M, et al. *Cancer Res*, 2009 Oct 1. PMID 19738061.